SCHEMBL3593976

SCHEMBL3593976

CN(C)C1Cc2c([NH])cccc2NC1=O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CREBBP Q92793 8/20 0.34
BRD4 O60885 7/20 0.34
BRPF1 P55201 1/20 0.34
KDM4E B2RXH2 3/20 0.33
LMNA P02545 1/20 0.33
CHRM2 P08172 1/20 0.33
CYP3A4 P08684 1/20 0.33
HTR1A P08908 1/20 0.33
ADRA2A P08913 1/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2C9 P11712 1/20 0.33
DRD2 P14416 1/20 0.33
ADRA2B P18089 1/20 0.33
DRD1 P21728 1/20 0.33
DRD4 P21917 1/20 0.33
DRD5 P21918 1/20 0.33
HTR2A P28223 1/20 0.33
MAPK1 P28482 1/20 0.33
CYP2C19 P33261 1/20 0.33
ADRA1A P35348 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3595539 0.85 HSP90AA1 (0.36) CREBBPBRD4BRPF1KDM4ELMNA
SCHEMBL3598948 0.83 HTR1A (0.34) CREBBPBRD4KDM4ELMNACHRM2
SCHEMBL3593980 0.83 HTR5A (0.35) CREBBPBRD4BRPF1HTR1AHTR2A
SCHEMBL3584555 0.82 DDB1 (0.36) CREBBPBRD4KDM4EDDB1CRBN
SCHEMBL3592385 0.82 TRPV1 (0.38) CREBBPBRD4KDM4ELMNACHRM2
SCHEMBL3590434 0.80 TRPV1 (0.41) KDM4ELMNACHRM2CYP3A4HTR1A
SCHEMBL3596675 0.77 BRD4 (0.33) CREBBPBRD4HTR1ADRD2DRD3
SCHEMBL3591905 0.72 CREBBP (0.39) CREBBPBRD4BRPF1KDM4ELMNA
SCHEMBL3595894 0.71 TRPV1 (0.30) CREBBPBRD4DDB1CRBN
SCHEMBL3601168 0.71 BRD4 (0.30) CREBBPBRD4DDB1CRBN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100016285-A1 HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2010-01-21 US disclosed
EP-2128157-A1 HETEROCYCLIDENE-N-(ARYL)ACETAMIDE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2009-12-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100016285-A1 HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE CCNY, CCND3, NSD3 CREBBP 2015/4885BRD4 706/4885BRPF1 2744/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.